Main comments The topic of this paper is important. However, the objective is not clear. I am not sure that "comparing differences" is correctly stated. Furthermore, according to the results section, there seems to be a focus on Aboriginal youth although no specific objectives or hypotheses are presented about this subgroup. I see two main objectives: To examine correlates of HCV infection at baseline among SY and to examine whether injection of PO is an independent predictor HCV incidence taking into account the effect of other injected substances and risk factors known to increase HCV risk among ???? (not clear) OR to examine the contribution of traditional and prescription drugs to the risk of HCV infection among….. Given the importance of injection drug use in HCV transmission, the analyses on the correlates of HCV prevalence and predictors of HCV incidence would be much more meaningful among youth injecting drugs. In fact, we know that injection drug use is THE main (if not the only) risk factor in this population. Comparing injectors of a given substance to other youth amounts at least partially, to comparing injectors to other youth since the reference group includes non injectors. Therefore risks are difficult to interpret. The analysis on syringe sharing is particularly disturbing since the reference group combines non injectors to injectors who do not share syringes. The questions inquiring about prescription opioid use should be presented. Was each drug named in the questionnaire, was it an open question… There is some literature showing that answers about the use of prescription drugs vary according to the question verbatim. More methodological details need to be briefly presented, e.g. definition of street involved youth (how was it operationalised), recruitment sites, follow up strategies. The refusal rate (or participation rate) should be presented. Univariate results of the three Cox regression models are not presented, except for gender, age and injection behaviours. What about the other variables mentioned in the method section?? The
sharing of other injection paraphernalia than syringes should also be considered in the modeling. Data are presented as if heroin injectors and PO injectors were two different groups. Figures about the proportion of youth injecting both substances should be presented. In fact many heroin injectors also inject POs when they cannot find the drug easily and experiment withdrawal symptoms or when they do not have enough money to afford heroin. Ethical issues are not addressed. The discussion is interesting and well written. Despite what I wrote above, I think that the hypothesis that PO injectors may be a somewhat different group is interesting. I suggest to do the analysis among injectors only, at least as a secondary analysis.
REVIEWER
Stephen Lankenau Drexel University, U.S.
REVIEW RETURNED
15-May-2014
GENERAL COMMENTS
The introduction is well written and highlights the significance of the potential link between prescription opioid (PO) injection and HCV among young IDUs compared to other well-known street drugs.
The longitudinal research design associated with the At-Risk Youth Study is sound with its large sample of street youth and HCV testing at baseline and during follow up.
The results provide important descriptive data on HCV prevalence and seroconversion during follow up. The descriptive data on history of PO and heroin injection at baseline and during follow up, however, is somewhat buried in the results section. This data should be more clearly reported. Also, the percentages are unclear, e.g., 4.2%. Is this a percentage of the entire sample, only IDUs, or something else? Additionally, since cocaine and methamphetamine injection are significantly associated with HCV, it would be useful to report the proportion who injected these drugs as well. Lastly, given the prevalence of participants who injected multiple drugs, it could be worth exploring to see if certain combinations, such as heroin and cocaine, were more commonly associated with HCV than others, such as heroin and opioids. Otherwise, the multivariate analyzes convincingly illustrate that PO injection is less relevant to HCV injection compared to other drugs.
The discussion is well written and adequately explains reasons for why PO might not be independently associated with HCV. The limitations acknowledges that the small number of PO injectors may be a factor as to why PO injection was not independently associated with HCV. Lastly, the authors recommend in the discussion section that PO injection should be a focal point of future studies so that this emerging and less understood practice can be more fully explored. This point could be re-emphasized in the conclusion.
VERSION 1 -AUTHOR RESPONSE
Comments, Reviewer #1:
1. The Reviewer asked that we reword our study objective. We have edited the final sentence of our Introduction section to read as follows:
Our study objective was to examine the contribution of injection of prescription opioids and that of traditional street drugs of abuse to the risk for HCV seroconversion.
2. The Reviewer noted that we had addressed drug use patterns specific to Aboriginal youth in our Methods and Results sectiosn, but had not specifically mentioned this subgroup in our Introduction section. Therefore, the following statement has been added:
We conducted the present study of HCV acquisition in Vancouver, Canada, among a prospective cohort of street youth, a population including a high proportion of Aboriginal youth who may be at elevated risk for blood-borne infection. 23 3. The Reviewer requested that we explicitly state the question inquiring about prescription opioid use. The relevant question has now been added to the Methods section:
Prescription opioids were broadly defined to include morphine, oxycodone, hydromorphone, meperidine, fentanyl or methadone. The exact question used was, "In the last 6 months, when you were using, which of the following drugs did you inject and how often?", with possible answers including, "Less than once per month / One to three times per month / About once per week / Two or three times per week / At least daily". Using this question, each of the prescription opioids listed above was individually and sequentially probed.
4.
The Reviewer asked that we present additional methodological details, including the definition of street-involved youth, recruitment sites, and follow-up strategies. The Methods section now includes the following:
Recruitment relied on extensive daytime and nighttime streetbased outreach and snowball sampling, and was systematically conducted in parks, streets and alleyways of Vancouver where street youth are known to congregate. Although no inclusion criterion explicitly required a minimum amount of time on the street to qualify for the study, in practice, the street-based recruitment resulted in a sample of youth who spent substantial time on the street, a large proportion of whom were homeless.
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[…] Additionally, a $5 CAN incentive was provided to youth three months after their baseline interview to return to the study site to update their contact information in an attempt to improve study follow-up.
Additionally, the Results section also includes the following to demonstrate that the sample was indeed highly street-involved:
The cohort spent a median of 12 hours on the street per day (IQR: 6-24 h).
5.
We agree with the Reviewer that the paper is improved by addressing the issue of participation rates. To address this comment the following text has been added to the second to last paragraph of the discussion section:
A final point regarding representativeness is the refusal rate among youth who are approached for enrolment into the study. Unfortunately, as youth often self-refer and street-based outreach often requires a very low threshold approach commonly involving repeated contact, rates of refusal can only be estimated. Study staff estimate that 30% of youth first approached for participation agree to be assessed for eligibility.
6. The Reviewer suggested we consider haring of injection paraphernalia other than syringes in our analyses. We conducted a sensitivity analysis and determined that use of other paraphernalia such as filters did not significantly alter results; rather, syringe sharing remained robust predictors in our models whereas other equipment did not maintain significance (data available upon request).
7. The Reviewer asked that we comment on the overlap between heroin and prescription opioid injectors. We have added the following text to the Discussion section:
Indeed, because injection of prescription opioids and of heroin were correlated in our sample, our results are consistent with other reports that many heroin injectors also inject prescription opioids when they cannot easily locate heroin or cannot afford it. 17 Additionally, the Results section reports:
Recent injection of prescription opioids and of heroin were correlated (p<0.05).
8. The Reviewer requested that we ensure ethical issues are addressed. These are highlighted in the Methods section:
ARYS was approved by the University of British
Columbia/Providence Health Care Research Ethics Board.
9. The Reviewer requested that, as a secondary analysis, we repeat our final multivariate model limiting the sample to only actively-injecting youth. This has been added. The Methods section now reads:
Finally, as a sub-analysis, we restricted the sample to druginjecting youth and examined bivariate associations between injection of prescription opioids, heroin, cocaine and crystal methamphetamine, and HCV seroconversion. We also repeated the third multivariate model using this subsample.
The Results section now also correspondingly reads: (unadjusted HR, 1.27;  95% CI, 0.57-2.84; p=0.555) . Heroin injection was associated with HCV seroconversion in this subsample (unadjusted HR, 2.93; 95% CI, 1.77-6.13; p<0.001), as was cocaine injection (unadjusted HR, 2.02; 95% CI, 1.11-3.68; p=0.021 Comments, Reviewer #2:
When the sample was restricted to only drug-injecting youth (n=166), prescription opioid injection was not associated with HCV seroconversion in bivariate analyses
1. The Reviewer requested that we make more prominent the data on history of prescription opioid and heroin injection at baseline and during follow-up. We have now moved this earlier in the Results section (before the description of the survival analyses) and given the data their own paragraph so as to make them more immediately available to the reader.
2. The Reviewer asked us to clarify the denominator when we reported that 4.2% injected prescription opioids in the first two years of the enrollment. We have now edited this sentence to highlight that this is a percentage of the entire sample (as are all subsequent percentages in the same sentence) in the Results section:
Over the study period, the prevalence of prescription opioid injection remained unchanged (4.2% of the entire sample in the first two years of enrollment vs. 4.4% in the last two years; p=0.880) as did that of heroin injection (13.5% vs. 11.8%; p=0.489).
3. The Reviewer asked that we report the proportion of participants injecting cocaine and crystal methamphetamine over the course of the study (in addition to the proportion of participants injection prescription opioids and heroin, which are already reported). We have added the following to the Results section:
[…] there was very little change in the prevalence of cocaine injection (12.2% of the entire sample in the first two years of enrollment vs. 10.0% in the last two years) and crystal methamphetamine injection (18.0% vs. 16.8%).
Additionally, the corresponding portion of the Methods section now reads:
[…] we examined the prevalence of prescription opioid injection and heroin in the first two years of study and that of the last two years of study to determine whether these behaviors were becoming more common with time. 14 We also examined prevalence of cocaine and crystal methamphetamine over the course of the study.
The Reviewer suggested we examine whether the combination of heroin and cocaine
imparted greater risk of HCV seropositivity. An interaction term examining the potential multiplicative effect of injecting both heroin and cocaine was not significant (data not shown).
Since the focus of the manuscript is on prescription opioids in comparison to other traditional street drugs of abuse, we have not included this interaction term in the manuscript, but would be happy to do so if the Editor wishes.
5. The Reviewer suggested we re-emphasize the recommendation that prescription opioid injection be the subject of future studies in the concluding paragraph of the Discussion section. This has been added, as follows:
Interestingly, although prescription opioid misuse is on the rise in North America, in our sample, risk of HCV acquisition from injection of prescription opioids did not exceed that of traditional street drugs, including heroin, cocaine and crystal methamphetamine. Nonetheless, prescription opioid injection should be the focus of further study to explore this emerging and poorly understood practice.
VERSION 2 -REVIEW

REVIEWER
Élise Roy University of Sherbrooke, Canada REVIEW RETURNED 27-Jun-2014
GENERAL COMMENTS
Although I still have some doubts about the relevance of examining the relative contributions of injecting different drugs to HCV seroconversion, using a sample that includes non IDU, I am satisfied with the modifications.
